The clinical outcome of SEA has been associated with various prognostic factors; however, reports on factors relating to motor function improvement after surgical treatment are limited.
OBJECTIVE: The aim of this study is to elucidate which clinical factors may affect motor function recovery after surgical treatment of SEA.
PATIENT AND METHODS: The clinical features of patients with SEA undergoing surgical drainage and antibiotics treatment were reviewed, check details and their outcomes were identified and analyzed.
RESULTS: The most common presenting symptoms were neck or back pain, motor deficits, and urinary incontinence. The most common underlying medical condition
was diabetes mellitus. Leukocytosis (P = .036; odds ratio [OR] = 0.754; confidence interval [CI] = 0.579-0.982), elevated C-reactive protein level (P = .017; OR 0.96; CI = 0.965-0.994), poor glycemic control (P = .012; OR = 23.33; CI = 1.992-273.29), and duration of motor deficit at the time of operation (P = .005; OR = 40.50; CI = 3.093-530.293) were found to have a strong influence
on motor function improvement after Selleck GDC-0449 surgical treatment.
CONCLUSION: Infection control and the prevention of further neurological deterioration in time are paramount in the treatment of SEA for optimal recovery. Patients with rapid neurological deterioration or higher white blood cell count or C-reactive protein level on presentation warrant aggressive surgical intervention; even in those who are Entospletinib completely paralyzed, an improvement in muscle power may still be possible.”
“Aim: Peroxisomes are known to play a role in cellular oxidative stress during pathogenesis of diabetes and hypertension.
We reported earlier that FPTIII (a farnesyl protein transferase inhibitor) attenuates ischemia-reperfusion injury and renal dysfunction in diabetic hypertensive (DH) rats. In this study, we have examined the effect of FPTIII on peroxisomal enzymes in relation to oxidative stress in kidneys of DH rats. Methods: Male Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were treated with streptozotocin (STZ) and/or FPTIII. Activities of key peroxisomal enzymes, catalase, acyl-CoA oxidase and beta-oxidation of lignoceric acid were measured in kidney homogenates. Lipid peroxidation in kidney was measured by malondialdehyde (MDA) assay. Results: Catalase activity was significantly (p < 0.01) reduced in diabetic WKY or SHR, and FPTIII markedly attenuated (p < 0.01) diabetes-induced inhibition of catalase. FPTIII also reduced STZ-induced increase in acyl-CoA oxidase activity. Fatty acid beta-oxidation and lipid peroxides were significantly increased in kidneys of DH rats. FPTIII reduced (p < 0.01) diabetes and hypertension-induced increase in fatty acid oxidation and lipid peroxides.